n Fresenius Medical Care AG & Co. KGaA reports strong operating results for the third quarter 2014 and confirms guidance for full year 2014
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Schlagwort(e):
Sonstiges
Fresenius Medical Care AG & Co. KGaA reports strong operating results
for the third quarter 2014 and confirms guidance for full year 2014
04.11.2014 / 07:23
---------------------------------------------------------------------
Fresenius Medical Care reports strong operating results for the third
quarter 2014 and confirms guidance
for full year 2014
- Third quarter shows strong organic revenue growth
- Operating cash flow on record level in third quarter
- Company remains on track to achieve full year guidance
Third quarter 2014 key figures:
Net revenue $4,113 million +12%
Operating income (EBIT) $590 million +6%
Net income $271 million -1%
Basic earnings per share $0.89 -1%
First nine months 2014 key figures:
Net revenue $11,511 million +7%
Operating income (EBIT) $1,591 million 0%
Net income $710 million -7%
Basic earnings per share $2.35 -6%
Rice Powell, chief executive officer of Fresenius Medical Care stated: "The
third quarter has confirmed the positive trend from the previous quarter.
Growth rates in revenue and earnings again improved and our operating cash
flow has reached an all time high for a single quarter. We are on track to
achieve our guidance as well as our cost savings target for the full year.
The recent acquisitions, in combination with financing activities were
important steps in the execution of our strategy to achieve our long term
target 2020."
Third quarter 2014
Revenue
Net revenue for the third quarter of 2014 increased by 12% to $4,113
million (+13% at constant currency) as compared to the third quarter of
2013. Organic revenue growth worldwide was 7%. Dialysis services revenue
grew by 14% to $3,197 million (+15% at constant currency) and dialysis
product revenue increased by 7% to $916 million (+7% at constant currency)
as compared to the third quarter of 2013.
North America revenue for the third quarter of 2014 increased by 11% to
$2,710 million. Organic revenue growth was 5%. Dialysis services revenue
grew by 12% to $2,498 million with a same store treatment growth of 3.5%.
Dialysis product revenue was flat compared to the third quarter of 2013 at
$212 million.
International revenue increased by 13% to $1,386 million (+16% at constant
currency). Organic revenue growth was 8%. Dialysis services revenue
increased by 19% to $699 million (+25% at constant currency). Dialysis
product revenue increased by 9% to $687 million (+9% at constant currency).
Earnings
Operating income (EBIT) for the third quarter of 2014 increased by 6% to
$590 million as compared to $557 million in the third quarter of 2013.
Operating income for North America for the third quarter of 2014 was $413
million, flat as compared to the third quarter of 2013. In the
International segment, operating income for the third quarter of 2014
increased by 26% to $269 million as compared to $214 million in the third
quarter of 2013.
Net interest expense for the third quarter of 2014 was $99 million,
compared to $103 million in the third quarter of 2013.
Income tax expense was $162 million for the third quarter of 2014, which
translates into an effective tax rate of 32.9%. This compares to income tax
expense of $148 million and a tax rate of 32.6% for the third quarter of
2013.
Net income attributable to shareholders of Fresenius Medical Care AG & Co.
KGaA for the third quarter of 2014 was $271 million, a decrease of 1%
compared to the corresponding number of $273 million for the third quarter
of 2013.
Basic earnings per share (EPS) for the third quarter of 2014 was $0.89, a
decrease of 1% compared to the corresponding number for the third quarter
of 2013. The weighted average number of shares outstanding for the third
quarter of 2014 was approximately 302.7 million shares, compared to 301.3
million shares for the third quarter of 2013. The increase in shares
outstanding resulted from stock option exercises in the past twelve months.
Cash flow
In the third quarter of 2014, the company generated $712 million in net
cash provided by operating activities, an increase of 18% compared to the
corresponding figure of last year and representing 17% of revenue.
A total of $224 million was spent for capital expenditures, net of
disposals. Free cash flow was $488 million compared to $430 million in the
third quarter of 2013.
A total of $613 million in cash was spent for acquisitions and investments,
net of divestitures. Free cash flow after investing activities was a
negative $125 million as compared to $235 million in the third quarter of
2013.
First nine months 2014
Revenue and earnings
Net revenue for the first nine months of 2014 increased by 7% to $11,511
million (+8% at constant currency) as compared to the first nine months of
2013. Organic revenue growth worldwide was 5%.
Operating income (EBIT) for the first nine months of 2014 was $1,591
million as compared to $1,595 million in the first nine months of 2013.
Net interest expense for the first nine months of 2014 was $294 million as
compared to $310 million in the first nine months of 2013.
Income tax expense for the first nine months of 2014 was $440 million,
which translates into an effective tax rate of 33.9%. This compares to
income tax expense of $421 million and a tax rate of 32.8% for the first
nine months of 2013.
For the first nine months of 2014, net income attributable to shareholders
of Fresenius Medical Care AG & Co. KGaA was $710 million, down by 7% from
the corresponding number of $761 million for the first nine months of 2013.
In the first nine months of 2014, basic earnings per share (EPS) was $2.35,
a decrease of 6% compared to the corresponding number for the first nine
months of 2013. The weighted average number of shares outstanding during
the first nine months of 2014 was approximately 302.0 million shares.
Cash flow
In the first nine months of 2014, the company generated $1,274 million in
net cash provided by operating activities as compared to $1,446 million for
the same period in 2013 and representing 11% of revenue.
A total of $639 million was spent for capital expenditures, net of
disposals. Free cash flow for the first nine months of 2014 was $635
million as compared to $952 million in the first nine months of 2013.
A total of $1,045 million in cash was spent for acquisitions and
investments, net of divestitures. Free cash flow after investing activities
was a negative $410 million as compared to $673 million in the first nine
months of 2013.
Employees
As of September 30, 2014, Fresenius Medical Care had 97,327 employees
(full-time equivalents) worldwide, compared to 89,282 employees at the end
of September 2013. This increase of more than 8,000 employees was
attributable to acquisitions as well as to our continued organic growth.
Balance sheet structure
The company's total assets were $24,253 million (Dec. 31, 2013: $23,120
million), an increase of 5%. Current assets increased by 3% to $6,459
million (Dec. 31, 2013: $6,287 million). Non-current assets were $17,794
million (Dec. 31, 2013: $16,833 million), an increase of 6%. Total equity
increased by 3% to $9,750 million (Dec. 31, 2013: $9,485 million). The
equity ratio was 40% as compared to 41% at the end of 2013. Total debt was
$9,068 million (Dec. 31, 2013: $8,417 million). As of September 30, 2014,
the debt/EBITDA ratio was 3.0 (Dec. 31, 2013: 2.8).
Please refer to the attachments for a complete overview of the results for
the third quarter and first nine months of 2014 and the reconciliation of
non-GAAP financial measures included in this release to the most comparable
GAAP financial measures.
Outlook
The company expects revenue to be at around $15.2 billion in 2014,
translating into a growth rate of around 4%. This outlook excludes revenue
of approximately $500 million from acquisitions completed during the first
nine months of 2014.
Net income attributable to shareholders of Fresenius Medical Care AG & Co.
KGaA is expected to be unchanged between $1.0 billion and $1.05 billion in
2014. The company initiated a global efficiency program designed to enhance
the company's performance over a multi-year period. Potential cost savings,
before income taxes, of up to $60 million generated from this program, and
net of implementation costs are not included in the outlook for 2014.
For 2014, the company expects to spend around $900 million on capital
expenditures. Reflecting the latest acquisitions the company now expects
acquisition spending of around $1.3 billion for fiscal year 2014
(previously $1 billion). The debt/EBITDA ratio is expected to be around 3.0
by the end of 2014.
Conference call
Fresenius Medical Care will hold a conference call to discuss the results
of the third quarter 2014 on Tuesday, November 4, 2014 at 3.30 p.m. CET/
9.30 a.m. EST. The company invites investors to follow the live webcast of
the call at the company's website www.fmc-ag.com in the "Investor
Relations" section. A replay will be available shortly after the call.
Fresenius Medical Care is the world's largest integrated provider of
products and services for individuals undergoing dialysis because of
chronic kidney failure, a condition that affects more than 2.5 million
individuals worldwide. Through its network of 3,349 dialysis clinics in
North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius
Medical Care provides dialysis treatments for 283,135 patients around the
globe. Fresenius Medical Care is also the world's leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
disposable products.
For more information about Fresenius Medical Care, visit the company's
website at www.fmc-ag.com.
Disclaimer
This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.
KGaA does not undertake any responsibility to update the forward-looking
statements in this release.
CONTACT
Fresenius Medical Care AG & Co. KGaA
Investor Relations
61352 Bad Homburg v. d. H.
Germany
www.fmc-ag.com
Oliver Maier
Head of Investor Relations &
Corporate Communications
Tel. +49 6172 609 2601
Fax +49 6172 609 2301
email: ir@fmc-ag.com
Published by
Fresenius Medical Care AG & Co. KGaA
Investor Relations
Annual reports, interim reports and further
information on the company is also available on our website.
Please visit us at www.fmc-ag.com
For printed material, please contact Investor Relations.
---------------------------------------------------------------------
04.11.2014 Veröffentlichung einer Corporate News/Finanznachricht,
übermittelt durch DGAP - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber
verantwortlich.
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,
Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap-medientreff.de und
http://www.dgap.de
---------------------------------------------------------------------
Sprache: Deutsch
Unternehmen: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Deutschland
Telefon: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-Mail: ir@fmc-ag.com
Internet: www.fmc-ag.de
ISIN: DE0005785802, DE0005785836,
WKN: 578580, 578583
Indizes: DAX
Börsen: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart; Terminbörse EUREX; NYSE
Ende der Mitteilung DGAP News-Service
---------------------------------------------------------------------
294808 04.11.2014
nn